43results about How to "Stable intercalation" patented technology

The invention provides adriamycin-containing medicine and a preparation method thereof. The medicine includes a nucleic acid nanoparticle and adriamycin, and the adriamycin is mounted on the nucleic acid nanoparticle; and the nucleic acid nanoparticle includes a nucleic acid structural domain, the nucleic acid structural domain contains an a sequence, a b sequence and a c sequence, and the a sequence contains an a1 sequence or a sequence of the a1 sequence in which at least one base is inserted, missed or replaced, the b sequence contains a b1 sequence or a sequence of the b sequence in whichat least one base is inserted, missed or replaced, and the c sequence contains a c1 sequence or a sequence of the c sequence in which at least one base is inserted, missed or replaced. According to the adriamycin-containing medicine, after the nucleic acid structural domain is modified by a target, targetability is good, adriamycin can be stably delivered, and reliability is high.

The application provides a drug containing tacrine, a preparation method for the drug, a pharmaceutical composition and application of the drug. The drug comprises a nucleic acid nanoparticle and thetacrine, and the tacrine is deposited on the nucleic acid nanoparticle; the nucleic acid nanoparticle includes a nucleic acid domain; the nucleic acid domain includes an a sequence, a b sequence and ac sequence; the a sequence includes an a1 sequence or a sequence of insertion, deletion or substitution of at least one base of the a1 sequence; the b sequence includes a b1 sequence or a sequence ofinsertion, deletion or substitution of at least one base of the b1 sequence; and the c sequence includes a c1 sequence or a sequence of insertion, deletion or substitution of at least one base of thec1 sequence. After the nucleic acid domain is modified by a target head, the drug containing the tacrine has a relatively good targeting property, can stably deliver the tacrine, and has very high reliability.

The invention provides a dihydroartemisinin-containing medicament, a preparation method thereof, a pharmaceutical composition and an application of the pharmaceutical composition. The medicament comprises nucleic acid nanoparticles and dihydroartemisinin, wherein the dihydroartemisinin is carried on the nucleic acid nanoparticles; the nucleic acid nanoparticles comprise a nucleic acid structural domain, wherein the nucleic acid structural domain comprises a sequence a, a sequence b and a sequence c; the sequence a comprises an a1 sequence or a sequence obtained by insertion, deletion or substitution of at least one base in the a1 sequence; the sequence b comprises a b1 sequence or a sequence obtained by insertion, deletion or substitution of at least one base in the b1 sequence; and the sequence c comprises a c1 sequence or a sequence obtained by insertion, deletion or substitution of at least one base in the c1 sequence. After the nucleic acid structural domain of the dihydroartemisinin-containing medicament provided by the invention is modified by a target head, the medicament can have better targeting property, can stably deliver dihydroartemisinin, and has high reliability.

The invention provides a cisplatin-containing medicine, a preparation method of the cisplatin-containing medicine, a medicine composition and application. The medicine comprises a nucleic acid nanoparticle and cisplatin mounted on the nucleic acid nanoparticle; and the nucleic acid nanoparticle comprises a nucleic acid structural domain, the nucleic acid structural domain comprises a sequence a, asequence b and a sequence c, the sequence a comprises a sequence a1 or a sequence obtained after insertion, deletion or substitution of at least one base of the sequence a1, the sequence b comprisesa sequence b1 or a sequence obtained after insertion, deletion or substitution of at least one base of the sequence b1, and the sequence c comprises a sequence c1 or a sequence obtained after insertion, deletion or substitution of at least one base of the sequence c1. After target head modification, the nucleic structural domain of the cisplatin-containing medicine has better targeting ability, can stably deliver cisplatin and has high reliability.

The invention provides a methotrexate-containing medicine, a preparation method, a medicinal composition and application thereof. The medicine comprises nucleic acid nanoparticles and methotrexate, wherein the methotrexate is mounted on the nucleic acid nanoparticles; the nucleic acid nanoparticles comprise nucleic acid structural domains, including a sequences, b sequences and c sequences; each asequence contains an a1 sequence or a sequence having at least one basic group inserted, lost or substituted on the a1 sequence; each b sequence contains a b1 sequence or a sequence having at least one basic group inserted, lost or substituted on the b1 sequence; and each c sequence contains a c1 sequence or a sequence having at least one basic group inserted, lost or substituted on the c1 sequence. After the nucleic acid structural domains are subjected to target head modification, the methotrexate-containing medicine has relatively good target performance, can be used for stably deliveringthe methotrexate and has high reliability.

The application provides a medicine containing oxaliplatin as well as a preparation method, a pharmaceutical composition and application thereof. The medicine comprises nucleic acid nanoparticles andoxaliplatin, wherein the oxaliplatin is mounted on the nucleic acid nanoparticles. The nucleic acid nanoparticle comprises a nucleic acid structural domain including a sequence a, a sequence b and a sequence c; the sequence a comprises a sequence a1 or a sequence in which at least one base is inserted, deleted or replaced in the sequence a1, the sequence b comprises a sequence b1 or a sequence inwhich at least one base is inserted, deleted or replaced in the sequence b1, and the sequence c comprises a sequence c1 or a sequence in which at least one base is inserted, deleted or replaced in thesequence c1. According to the oxaliplatin-containing medicine provided by the invention, the nucleic acid structural domain of the is modified by the target head, so that the good targeting propertyis realized; oxaliplatin can be delivered stably; and the reliability is high.

The application provides a drug containing pirarubicin, a preparation method for the drug, a pharmaceutical composition and application of the drug. The drug comprises a nucleic acid nanoparticle andthe pirarubicin, and the pirarubicin is deposited on the nucleic acid nanoparticle; the nucleic acid nanoparticle includes a nucleic acid domain; the nucleic acid domain includes an a sequence, a b sequence and a c sequence; the a sequence includes an a1 sequence or a sequence of insertion, deletion or substitution of at least one base of the a1 sequence; the b sequence includes a b1 sequence or asequence of insertion, deletion or substitution of at least one base of the b1 sequence; and the c sequence includes a c1 sequence or a sequence of insertion, deletion or substitution of at least onebase of the c1 sequence. After the nucleic acid domain is modified by a target head, the drug containing the pirarubicin has a relatively good targeting property, can stably deliver the pirarubicin,and has very high reliability.

The application provides a gemcitabine-containing medicine and a preparation method thereof, and a pharmaceutical composition and an application thereof. The medicine comprises nucleic acid nanoparticles and gemcitabine, and besides, the gemcitabine is carried on the nucleic acid nanoparticles; and the nucleic acid nanoparticles comprise a nucleic acid domain, the nucleic acid domain comprises a sequence a, a sequence b and a sequence c, the sequence a comprises a sequence a1 or a sequence of the sequence a1 with at least one base insertion, deletion or substitution, the sequence b comprises asequence b1 or a sequence of the sequence b1 with at least one base insertion, deletion or substitution, and the sequence c comprises a sequence c1 or a sequence of the sequence c1 with at least onebase insertion, deletion or substitution. After the nucleic acid structural domain is modified by a target head, the provided gemcitabine-containing medicine has relatively good targeting property, can stably deliver the gemcitabine and is very high in reliability.

The invention provides a paclitaxel-containing medicine, and a preparation method, a pharmaceutical composition and an application thereof. The medicine comprises a nucleic acid nanoparticle and paclitaxel, and the paclitaxel is loaded on the nucleic acid nanoparticle; and the nucleic acid nanoparticle comprises a nucleic acid structural domain, the nucleic acid structural domain comprises a sequence a, a sequence b and a sequence c, the sequence a comprises a sequence a1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence a1, the sequence b comprises a sequence b1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence b1, and the sequence c comprises a sequence c1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence c1. After the nucleic acid structural domain is modified with a target head, the paclitaxel-containing medicine has a good targeting property, can stably deliver the paclitaxel, and has a very high reliability.

The application provides medicine containing aspirin, a preparation method of the medicine containing aspirin, a medicine composition and application. The medicine comprises nucleic acid nanoparticlesand the aspirin, wherein the aspirin is hung and loaded on the nucleic acid nanoparticles; the nucleic acid nanoparticles comprise a nucleic acid structural domain; the nucleic acid structural domaincomprises a sequence a, a sequence b and a sequence c; the sequence a comprises a sequence a1 or a sequence obtained by performing insertion, deletion or substitution of at least one base on the sequence a1; the sequence b comprises a sequence b1 or a sequence obtained by performing insertion, deletion or substitution of at least one base on the sequence b1; and the sequence c comprises a sequence c1 or a sequence obtained by performing insertion, deletion or substitution of at least one base on the sequence c1. The medicine containing aspirin provided by the invention has the advantages thatafter the nucleic acid structural domain is modified by a target head, good targeting performance is realized; the aspirin can be stably delivered; and the reliability is very high.

The application provides a medicine containing epirubicin, a preparation method, a medicine composition and application thereof. The medicine comprises nucleic acid nanoparticles and the epirubicin, and the epirubicin is mounted on nucleic acid nanoparticles. Nucleic acid nanoparticles include a nucleic acid domain, and the nucleic acid domain contains a a sequence, a b sequence and a c sequence.The a sequence contains a a1 sequence or a sequence that at least one base insertion, base deletion or base substitution occurs in a1 sequence. The b sequence contains a b1 sequence or a sequence thatat least one base insertion, base deletion or base substitution occurs in b1 sequence. The c sequence contains a c1 sequence or a sequence that at least one base insertion, base deletion or base substitution occurs in c1 sequence. After the nucleic acid domain is modified by the target head, the medicine containing epirubicin provided by the present application has better targeting, can stably delivers epirubicin, and has high reliability.

The invention provides a flavones-containing medicine, a preparation method thereof, a medicine composition and application. The medicine comprises nucleic acid nanoparticles and flavones, wherein theflavones are hung on the nucleic acid nanoparticles; the nucleic acid nanoparticles comprise a nucleic acid structure domain; the nucleic acid structure domain comprises a sequence a, a sequence b and a sequence c; the sequence a comprises a sequence a1 or a sequence that at least one base group is inserted, deleted or replaced in the sequence a1; the sequence b comprises a sequence b1 or a sequence that at least one base group is inserted, deleted or replaced in the sequence b1; and the sequence comprises a sequence c1 or a sequence that at least one base group is inserted, deleted or replaced in the sequence c1. After target head modification on the nucleic acid structure domain, the flavones-containing medicine provided by the invention has good targeting performance, is capable of stably delivering the flavones and is high in reliability.

The invention discloses a spliced type outdoor display screen structurally comprising a protection plate, a controller, a rotating rod, gap rotating teeth, an adjusting device, an elastic rod, displayscreen bodies, a frame body and a supporting rod; after the improvement, when the spliced type outdoor display screen is used, the display screen bodies are buckled on a positioning frame in parallel; supporting push blocks are connected to the rear portions of the display screen bodies, and adsorption strips can be mounted on the display screen bodies due to the acting force of the supporting push blocks; suckers can firmly adsorb the display screen bodies without loosening due to the strong adsorption force of bionic octopus, so the display screen bodies can be stably mounted on the positioning frame, and the use stability of the display screen bodies is improved. The position of a swing rod is adjusted left and right on a dial through a rotating shaft, after the swing rod is adjusted to a certain position on a sliding rail, the inner wall of a buckle is matched with an elastic buckle, the elastic buckle is fixedly clamped on a lock catch, the flatness, perpendicularity and levelness of spliced display screen bodies are located on the same plane, and the display effect of the display screen is improved.

The invention provides a docetaxel-containing medicine, and a preparation method, a pharmaceutical composition and application thereof. The medicine comprises nucleic acid nanoparticles and docetaxel,and the docetaxel is mounted on the nucleic acid nanoparticles; the nucleic acid nanoparticles comprise a nucleic acid domain, the nucleic acid domain comprises a sequence a, a sequence b and a sequence c. The sequence a comprises a sequence a1 or a sequence in which at least one base is inserted, deleted or replaced in the sequence a1; the sequence b comprises a sequence b1 or a sequence in which at least one base is inserted, deleted or replaced in the sequence b1; and the sequence c comprises a sequence c1 or a sequence in which at least one base is inserted, deleted or replaced in the sequence c1. After the nucleic acid domain of the docetaxel-containing medicine is modified by a target head, the docetaxel-containing medicine provided by the invention has relatively good targeting property, can stably deliver the docetaxel, and is very high in reliability.